Better survival of renal cell carcinoma in patients with inflammatory bowel disease
Open Access
- 5 October 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (35) , 38336-38347
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Lauranne A.A.P. Derikx1, Loes H.C. Nissen1, Joost P.H. Drenth1, Carla M. van Herpen2, Wietske Kievit3, Rob H.A. Verhoeven4, Peter F.A. Mulders5, Christina A. Hulsbergen-van de Kaa6, Marye J. Boers-Sonderen2, Tim R.A. van den Heuvel7, Marieke Pierik7, Iris D. Nagtegaal6, Frank Hoentjen1, On behalf of the Dutch Initiative on Crohn and Colitis (ICC), PALGA group and IBD/RCC group 1Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Radboud university medical centre, Nijmegen, The Netherlands 2Department of Medical Oncology, Radboud university medical centre, Nijmegen, The Netherlands 3Radboud Institute for Health Sciences, Radboud university medical centre, Nijmegen, The Netherlands 4Netherlands comprehensive cancer organization / Netherlands Cancer Registry, Utrecht, The Netherlands 5Department of Urology, Radboud university medical centre, Nijmegen, The Netherlands 6Department of Pathology, Radboud university medical centre, Nijmegen, The Netherlands 7Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands Correspondence to: Lauranne A.A.P. Derikx, e-mail: Lauranne.Derikx@radboudumc.nl Keywords: inflammatory bowel disease, renal cell carcinoma, immunosuppressive therapy Received: June 30, 2015 Accepted: September 24, 2015 Published: October 05, 2015 ABSTRACT Background: Immunosuppressive therapy may impact cancer risk in inflammatory bowel disease (IBD). Cancer specific data regarding risk and outcome are scarce and data for renal cell carcinoma (RCC) are lacking. We aimed(1) to identify risk factors for RCC development in IBD patients (2) to compare RCC characteristics, outcome and survival between IBD patients and the general population. Methods: A PALGA (Dutch Pathology Registry) search was performed to establish a case group consisting of all IBD patients with incident RCC in The Netherlands (1991–2013). Cases were compared with two separate control groups: (A) with a population-based IBD cohort for identification of risk factors (B) with a RCC cohort from the general population to compare RCC characteristics and outcomes. Results: 180 IBD patients with RCC were identified. Pancolitis (OR 1.8–2.5), penetrating Crohn’s disease (OR 2.8), IBD related surgery (OR 3.7–4.5), male gender (OR 3.2–5.0) and older age at IBD onset (OR 1.0–1.1) were identified as independent risk factors for RCC development. IBD patients had a significantly lower age at RCC diagnosis (p < 0.001), lower N-stage (p = 0.025), lower M-stage (p = 0.020) and underwent more frequently surgical treatment for RCC (p < 0.001) compared to the general population. This translated into a better survival (p = 0.026; HR 0.7) independent of immunosuppression. Conclusions: IBD patients with a complex phenotype are at increased risk to develop RCC. They are diagnosed with RCC at a younger age and at an earlier disease stage compared to the general population. This translates into a better survival independent of immunosuppressive or anti-TNFα therapy.Keywords
This publication has 39 references indexed in Scilit:
- Use of Immunosuppressants and Biologicals in Patients with Previous CancerDigestive Diseases, 2013
- Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term surveyJournal of Gastroenterology, 2012
- A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinomaBritish Journal of Cancer, 2010
- Why Match? Investigating Matched Case-Control Study Designs with Causal Effect EstimationThe International Journal of Biostatistics, 2009
- No improvement in renal cell carcinoma survival: A population-based study in the NetherlandsEuropean Journal of Cancer, 2008
- Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High DoseJournal of Clinical Oncology, 2007
- Immunosuppressive Therapy and Malignancy in Organ Transplant RecipientsDrugs, 2007
- Ulcerative colitis and renal cell carcinoma.Gut, 1996
- Ulcerative colitis complicated by renal cell carcinoma: a series of three patients.Gut, 1996
- Completeness of Cancer Registration in Limburg, the NetherlandsInternational Journal of Epidemiology, 1993